🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
15.87
-0.15 (-0.94%)
At close: Nov 18, 2026, 4:00 PM EST
15.87
0.00 (0.00%)
After-hours: Nov 18, 2026, 4:10 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Q1 DM1 registrational data are expected, with management anticipating significant vHOT and splicing results. A DMD exon 51 decision is expected in January, followed by a planned Q1 launch; shared infrastructure is intended to support global expansion and a seven-product portfolio.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. We're going to get started with the next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have the Dyne team with me. To my direct right is John Cox, CEO, and to his right is Erick Lucera, CFO. Welcome, both of you.

John Cox
CEO, Dyne Therapeutics

Thank you.

Andrew Tsai
Senior Biotech Analyst, Jefferies

So maybe give us an introduction about Dyne, first and foremost, what your differentiation is, what you're trying to achieve, milestones over the next 3-12 months could also be helpful.

John Cox
CEO, Dyne Therapeutics

Yeah. Thank you. And thanks for having us, Andrew. Well, 2026 has been one incredible year for this company, a transforming year for the company, in terms of clinical progress, regulatory progress, and essentially building the kind of scale and infrastructure we need to transform certain markets next year, DMD being the first that we expect to launch our first product in. Getting back to what we're trying to do and accomplish as a company, this company was founded on the notion that in neuromuscular genetic disorders, the elegant nucleotide or nucleic acid sequences are known. But maybe one of the biggest biotech hurdles or challenges has been how to deliver those nucleic acids in sufficient quantity broadly and deeply enough to tissue.

This company developed a platform that we call the FORCE platform to do that. I think our scientists have overcome what is one of the biggest biotech challenges. We demonstrated that at the end of last year in two very difficult diseases, DMD and myotonic dystrophy type one. In both of those diseases, we showed clinically in humans using the same delivery platform that we were able to generate functional improvement across multiple efficacy measures, not slowing of decline, but actual improvement from baseline. That's never been seen before. It's a remarkable accomplishment. We went into this year thinking deeply about our capital allocation strategy for our shareholders. It's good to have Erick here, and he can talk about that some more.

That strategy was to make sure we're investing in regulatory and regulatory execution, clinical and clinical execution across multiple trials and late-stage trials, and to build out our commercial organization to prepare ourselves to be able to launch these products ourselves in the U.S. That's going to be happening, we believe, beginning next year in Q1. We also have some very important data in DM1 that I'm sure you're going to want to talk about that we expect to turn over, registrational endpoint data that we expect to turn over in Q1 of this year as well, this coming year.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. Maybe this time around, I would love to ask on DM1 first for the Q1 readout. To start off, the elephant in the room is Novartis did fail recently on their own phase III. On one hand-- what's interesting is Novartis still sees a path forward. On one hand, I think you guys could be the first mover. On the other hand, the primary endpoint for your own pivotal study for Accelerated Approval is also vHOT. Can you reassure investors why you guys will show stat sig on vHOT?

John Cox
CEO, Dyne Therapeutics

Yeah, I'm happy to. First of all, I think everybody was disappointed in the Novartis result. I think it was unfortunate for the field and for the patients. We were surprised because the endpoint that you're referring to, video hand opening time, which is a reflection of myotonia, is an endpoint that moves very easily. I think everybody expected that to be easy to hit as long as you had a dose that was generating sufficient splicing correction. I just remind people that the core kind of pathobiology of this disease is it is a splicing or mis-splicing issue occurring in the nucleus of the cell throughout most of the cells of the body. You have to have a dose that's engaging in the nucleus.

I say that because our product, which gets to your question why we still believe, is that our product uses a very different payload than the Novartis drug. We use an antisense oligonucleotide. We use that intentionally because it is designed to get to the nucleus where the core issue is. We have demonstrated very clearly splicing correction through our dose escalation and at our highest dose, and sufficient splicing correction not only to correct or improve on vHOT and hand myotonia, but on a variety of even more important functional measures. I will just add that for us, vHOT is an endpoint that we are using as an intermediate clinical endpoint, not as a phase III endpoint. It is being used as an intermediate clinical endpoint for Accelerated Approval. It is an early indicator.

Frankly, it is not that clinically meaningful, but it is an early indicator of other functional benefit of which we need to show trends for Accelerated Approval. So, we have looked at the stats. We have 71 patients in this registrational expansion cohort, and we believe we will be stat sig on vHOT. We think we will be statistically significant on splicing correction, and we also believe that we should see trends in multiple functional measures that really matter to this community.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Got it. Thank you. I suspect, I do not know the answer, Novartis, for them to move forward and mentioning, it sounds like they saw hints of efficacy in other endpoints outside of vHOT. I suspect that the placebo for vHOT was a bit noisy. Again, I do not know. It begs the question, did you guys factor in a placebo response? In terms of trial execution, how have you tried to curb for a placebo response?

John Cox
CEO, Dyne Therapeutics

I do not think like you. I am just hearing about what may have happened with the Novartis. It is all speculation. Hopefully, there will be some data presented at an upcoming conference. I think they have indicated they would do that. I will just tell you how we have handled it from a vHOT standpoint. First of all, we saw vHOT improve at our lowest dose of 1.8 mg per kg. Not the dose we are using for registration, but 1.8 mg per kg. We went all the way up to 6.8 mg per kg, so we know we are well above where we need to be for pharmacological activity. In terms of our placebo studies, as we have done that work with our multi-center dose, I think we had 14 placebo patients. We saw there is, of course, variability from patient to patient.

The key is that you don't have variability within the patient, or for that given patient. But what we saw with the placebo is that we saw a slight worsening of placebo of about 0.4 seconds. That's pretty consistent with natural history, and there's plenty of papers. I think there's a paper out recently by Leeuwenberg, really on vHOT, talking about the stability of vHOT over time for a given patient. So, I think the idea of random placebo issues is really a matter of conducting the test in a rigorous way, and we've been doing that. We have put a tremendous amount of effort through our studies on how we do the testing, the training by master physical therapists on how the test should be done for each site.

We have the same physical therapist with that patient through the testing periods, so you don't have kind of tester variability, and I could go on. We take duplicates. So, the key here is to make sure that you are getting an accurate, truthful baseline number when you do it, and I think we've taken the right steps to make sure that happens.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks. Speaking of the baseline, you recently shared the baseline scores of vHOT for your pivotal cohort that reads out in Q1. So, what's the take-home message there, and do the values there make you more confident that this upcoming study will succeed?

John Cox
CEO, Dyne Therapeutics

Well, I think they do. I'll tell you the intent of that work. Listen, we had anticipated that at World Muscle, that Novartis would be presenting data for 12-month data. They would pass on vHOT, and that we would get to see what they were getting on some of the other functional measures at 12 months. What we were trying to do most recently was put together a cohort of 25 patients and present that data in terms of the functional measures at 12 months, so you could compare. But we also provided six-month vHOT data. We also provided, as you said, the baseline mean data for vHOT for the registrational expansion cohort of 71 patients. If you start comparing those baseline kind of means, they're comparable across the MAD, across that summed-up group of cohorts that we had of 25 patients, and with the 71 patients.

What that does is tell you that what we ought to see in the 71 with the REC will be similar to what we've seen previously with the MAD. That's what our stats have all been based on. So, we're comforted by seeing the baseline, the baseline standard deviation, and how it kind of compares to natural history, et cetera. It also speaks, I think, a lot to how disciplined we have been about inclusion/exclusion criteria and the rigor of which we've conducted every aspect of this clinical development program.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Very good. As we think about the Accelerated Approval pathway, vHOT obviously needs to hit stat sig as your primary endpoint. You mentioned your confidence splicing hitting stat sig. Is that necessary for Accelerated Approval, or is it more about the outcome measures you're measuring?

John Cox
CEO, Dyne Therapeutics

It's not necessary. It's certainly helpful because I believe the FDA understands full well the importance of splicing and its implications for effect on the disease. To be clear on Accelerated Approval, that type of pathway, you are expected to have statistical significance on either an intermediate clinical endpoint or a molecular biomarker. We should have statistical significance on vHOT as the intermediate clinical endpoint. We should have statistical significance on a molecular biomarker, splicing correction. Then the other expectation is that in addition to hitting on the vHOT, that you would see trends, a reason to believe that that early indicator will have functional effect over time. Those trends do not have to be stat sig. But you've seen, Andrew, you've seen our trends.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes.

John Cox
CEO, Dyne Therapeutics

You don't have to squint to see that those trends are showing improvement relative to baseline and/or placebo across multiple functional measures.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Got it. Just to clarify, you're evaluating maybe four or five outcome measures. As long as one out of five, at least, shows a trend, you're good.

John Cox
CEO, Dyne Therapeutics

Well, with Accelerated Approval, it's in the eyes of the FDA.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood, yeah.

John Cox
CEO, Dyne Therapeutics

You've seen Accelerated Approvals happen with one trend, sometimes very low correlations for diseases that are rare and difficult and for which a drug is needed. We've seen those types of trends across quantitative muscle testing, timed function tests, like 10-meter walk/run, five-time sit to stand. We've even seen it on patient-reported outcomes, even at the highest dose and the registrational dose, we saw those trends, very clear trends on CNS effect on the CNS subscales of MDHI. I'd be surprised if there's just one answer.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I understand. Yeah. Okay. Hypothetically speaking, if this cohort, or sorry, this pivotal cohort did not succeed on vHOT, you technically have two shots on goal because, like you said, you are running the phase III confirmatory study. Is that the right way to think about it? If so, when could the confirmatory data be?

John Cox
CEO, Dyne Therapeutics

I will let Erick run with this.

Erick Lucera
CFO, Dyne Therapeutics

Yeah. As you mentioned, we are running a phase III confirmatory trial, called HARMONIA, which has 150 patients randomized one-to-one. We have not given timelines yet for when that will be completed, but a good analog would be Avidity, where they had a similar trial, 150 patients, one-to-one, took about 16 months to enroll. The endpoint for our trial is five-time sit to stand, and we have done a tremendous amount of work with KOLs, and we believe that is absolutely the best primary endpoint to have for these patients, because it really does show the effect of the drug in terms of giving people quality of life. It measures the whole body, and standing up from a chair is not the easiest thing to do.

It is a very rigorous test, and we think it is an endpoint that, as clinicians and even investors start to do the work on it, they are going to come to see that we made the right choice.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes. Avidity took 16 months to enroll and then another year for data. Is that how I can think about it as an analog?

Erick Lucera
CFO, Dyne Therapeutics

That's a good analog.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Erick Lucera
CFO, Dyne Therapeutics

It's the only one out there.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes. Back to this pivotal readout. How should we think about the safety profile? Any SAEs, drug-related SAEs we should be thinking about?

John Cox
CEO, Dyne Therapeutics

We had our last safety update not too long ago, and there have been no serious TEAEs. If that changes, I mean, we monitor, obviously in a blinded way, and if that changed in some material way, we'd let you know. But the safety profile has been, I think, in our opinion, quite favorable.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Very good. So good luck on that data readout. Seems like you've executed well. Fingers crossed. Then shifting gears to DMD exon 51, where the PDUFA is January, which I feel like could be before DM1. You don't need to say if so. But you're launching in Q1, it sounds like.

John Cox
CEO, Dyne Therapeutics

That's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

How have the FDA discussions been going so far?

John Cox
CEO, Dyne Therapeutics

Well, it's 66 days. We have a countdown clock in our--

Andrew Tsai
Senior Biotech Analyst, Jefferies

Several.

John Cox
CEO, Dyne Therapeutics

--main building. It's 66 days. We just, as kind of a matter of policy, have not been providing kind of play-by-play regulatory, so we're not going to do it. We're just too close to our PDUFA date, so we won't be commenting.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. As I think about the label, to the extent you are willing to share, what could be included in the Section 14 of the label? Is it just dystrophin, or because you did see these nice outcome measures, could that also be included?

John Cox
CEO, Dyne Therapeutics

With Accelerated Approval, that is also up to the FDA. Normally, you want to get as much in the label as you can, and I'd love to do that. But I will tell you, for a rare disease like this, in DMD, the doctors know the data, the families know the data, everybody is familiar with it. If you look at the current, if you want to call it, I guess the standard of care would be eteplirsen today. They have a broad label in terms of age and so on. I would expect at a minimum, we'd have our dystrophin data in there. But the more that we have in there on function, that's great, but I don't think that's a prerequisite for us to have a successful launch.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Makes sense. In terms of price, you've frequently mentioned EXONDYS being a million-dollar price point. Is that the floor on price?

Erick Lucera
CFO, Dyne Therapeutics

Well, obviously, it's a little too early to comment specifically on pricing, but I think the EXONDYS example is a good one for folks to use in their models. As a reminder, we are bringing patients a lot of value for this drug. The current therapy is administered weekly, and we're monthly. They don't have a lot of function, if any, data out there in their label. We've got six functional endpoints to drive value for these patients, in addition to a significant increase in dystrophin relative to standard of care. So, we think we're bringing a great value to the community, and we'll announce pricing when we got it locked down.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Sounds good. Let's just say you are approved in January. How many weeks does it take for you to actually launch? Would you--

John Cox
CEO, Dyne Therapeutics

We're saying it'll be in Q1. Typically, there is a short period of time. There's a short period of time after you get approval that just getting supply through and out to patients takes a little bit of time, but that'll be normal.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Do you plan to provide free drug at all, or is this--

John Cox
CEO, Dyne Therapeutics

Right now, the inventory plans and strategies are to make sure that we keep all the clinical patients on drug, that we are supplying for the phase III, and also that we are building inventory and ready for a successful commercial launch. So that's really the focus right now.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. In terms of the market opportunity, EXONDYS, we've discussed this before, I believe, 500 patients in the U.S., but there's also a pool of naive patients, 500, and then discontinuations, 500 patients too. So 1,500 total. Where is the low-hanging fruit in your view in the first year?

John Cox
CEO, Dyne Therapeutics

You want to?

Erick Lucera
CFO, Dyne Therapeutics

I think our intention is to get this drug to every boy that we can. We don't see it as sort of low-hanging fruit. This is a therapy that these boys need, and it's our moral duty to make sure that we get as many of these kids on this as fast as possible.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes.

John Cox
CEO, Dyne Therapeutics

I think the way it breaks out is, we've been estimating about 1,600. We have been building out a commercial organization. The last two years have been building a leadership team, and the last kind of nine months to a year has been under Johanna Friedl-Naderer building out, I think, a world-class rare disease neuromuscular expert group of people. That includes people that are working with payers already, focused on market access, and understanding the market. So we think there's about 1,600 patients out there, maybe 500 or so on the current treatment of eteplirsen. There's probably another 500 that had tried eteplirsen and dropped off of it. So, I would think those groups in particular would be particularly attentive to this launch.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see.

Erick Lucera
CFO, Dyne Therapeutics

That's just U.S.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Right. Then, oh, you had a question? Okay.

Speaker 4

John, in the event that you're approved, how can you take that approval and kind of make it a flywheel as opposed to each specific mutation kind of becomes its kind of own set of toxicology, own [inaudible]

John Cox
CEO, Dyne Therapeutics

Yeah. I'm glad you raised it, [Chris]. For those that may not have heard the question, listen, when we talk about the patients today and what we just quoted, the 1,600 is about 13% of that entire DMD population in the U.S. We have already taken our platform, and Ron Batra, who is our CSO, has already created the drug candidates, and we're moving them through our pre-IND process. Because they're so de-risked, I mean, exon 51 is arguably the toughest exon to skip. So we have the exon skipping data in our models. We're moving those forward. I'll tell you, our ambition here is to become leaders in DMD, and it is to go beyond exon 51 and build from that a flywheel, as you describe it.

The next step with that is once we have this first drug approved with the FDA, is to sit down with the FDA, and they have so many wonderful initiatives that you've been hearing about. Certainly the ambition of the FDA now to be able to get these types of drugs to patients in a streamlined way, I think we should be front and center of that effort, and we intend to be.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Then, maybe a couple more questions on the commercial side. How many sales reps do you need? What do COGS look like?

Erick Lucera
CFO, Dyne Therapeutics

Yeah. This is a prototypical rare disease market. We haven't disclosed the specific number of reps yet. But if you think about it, there's about 100 centers in the U.S. where 80% of the boys are. So it's a pretty dense group. So we feel like we can have a very capital-efficient commercial model that we will use not only for DMD, but the same organization that will scale a little bit for DM1, and then add the other four exons to it, plus FSHD. So we have the opportunity to have seven different products all running through the same commercial organization. In addition to the second part of your question with respect to cost of goods, those same drugs will also be running through the same CMC process, same Fab, same linker, et cetera, et cetera.

We expect in the beginning, a lot of the COGS will be inventory that's already been expensed for R&D. But as we scale it, we do expect to get to ADC-like gross margins over time. So we think the combination of having seven products all through the same commercial and manufacturing infrastructure should allow us to, as we get into the next decade, have above average growth rates, above average profitability margins, and a really great specialty pharma story.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. Then, ex-U.S. opportunity, because I feel like EXONDYS has made good traction there too, but I'd imagine you want to go ex-U.S. yourself. So what's the strategy there?

John Cox
CEO, Dyne Therapeutics

I mentioned that we have these confirmatory phase IIIs. They are confirmatory from the standpoint of supporting Accelerated Approval in the U.S., but they are phase IIIs from a global perspective. There is some EXONDYS in places like the Middle East, but Europe does not have drugs available for DMD. That market is the size of the U.S. market. They desperately need these types of therapies, and we are conducting a phase III that we think will definitively allow us to get approval there. Japan is the same story. We wholly own the assets. We have not partnered them. It is an opportunity for us to be able to go global in a sequential way and through the same infrastructure for both drugs commercially and CMC, as Erick was saying.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Let me, last question. Timelines for the remaining earlier stage programs. We have discussed the other exons. There is FSHD, Pompe. When do those enter the clinic?

John Cox
CEO, Dyne Therapeutics

The other exons are clearly a priority. FSHD is also a real priority for us. I think our platform is ideally suited for addressing that disease because of the depth and breadth that we get to the tissue, and that is going to be needed. FSHD, we have an IND approved, and we are moving forward towards the clinic right now. Hopefully we can talk more about that in the coming year.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. I think that is all the time we have. Thank you so much for the updates.

Erick Lucera
CFO, Dyne Therapeutics

Thank you.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Best of luck.

John Cox
CEO, Dyne Therapeutics

Thank you.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks, everyone.